Director/PDMR Share Dealings
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your CREO notes
Further to the announcements made on 30 September 2024 and 18 October 2024, and pursuant to the recent fundraising, the Company confirms that the following directors of the Company have acquired New Ordinary Shares at the Issue Price of 24 pence per Ordinary Share as follows:
| Director/PDMR Name | No. of New Ordinary Shares Acquired | Resultant Shareholding post transaction | % of voting rights post transaction |
|---|---|---|---|
| Kevin Crofton | 2,916,666 | 3,566,666 | 0.87% |
| Richard Rees | 208,333 | 3,036,540 | 0.74% |
Creo Medical Group plc www.creomedical.com Richard Craven, Company Secretary Via Walbrook PR Cavendish Capital Markets Limited (Nominated Adviser, Joint Bookrunner and Joint Broker) +44 (0)20 7220 0500 Stephen Keys / Camilla Hume / George Lawson (NOMAD) Michael Johnson (Sales) Deutsche Numis (Joint Bookrunner and Joint Broker) Freddie Barnfield / Duncan Monteith / Euan Brown William Baunton (ECM) +44 (0)20 7260 1000 Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com Paul McManus / Phillip Marriage Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Kevin Crofton | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Chairman | |
| b) | Initial notification/Amendment | Initial Notification | |
| a) | Name | Creo Medical Group plc | |
| b) | LEI | 213800H188ZDCWWXFA21 | |
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.001 each | |
| Identification code | GB00BZ1BLL44 | ||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volumes(s) | Price(s) | Volume(s) |
| £0.24 | 2,916,666 | ||
| d) | Aggregated information | N/A single transaction | |
| Aggregated volume | N/A single transaction | ||
| Price | N/A single transaction | ||
| e) | Date of the transaction | 21 October 2024 | |
| f) | Place of the transaction | London Stock Exchange | |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Richard Rees | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer | |
| b) | Initial notification/Amendment | Initial Notification | |
| a) | Name | Creo Medical Group plc | |
| b) | LEI | 213800H188ZDCWWXFA21 | |
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.001 each | |
| Identification code | GB00BZ1BLL44 | ||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |
| c) | Price(s) and volumes(s) | Price(s) | Volume(s) |
| £0.24 | 208,333 | ||
| d) | Aggregated information | N/A single transaction | |
| Aggregated volume | N/A single transaction | ||
| Price | N/A single transaction | ||
| e) | Date of the transaction | 21 October 2024 | |
| f) | Place of the transaction | London Stock Exchange |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.